EP
NAGE

Essential Partners’s Niagen Bioscience NAGE Stock Holding History

Essential Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$724 Sell
227
-1,157
-84% -$4.7K ﹤0.01% 2373
2026
Q1 		$6.1K Sell
1,384
-2,461
-64% -$13.3K ﹤0.01% 1486
2025
Q4 		$24.5K Sell
3,845
-874
-19% -$6.08K 0.01% 834
2025
Q3 		$44K Buy
4,719
+467
+11% +$4.71K 0.01% 629
2025
Q2 		$61.3K Buy
+4,252
New +$42K 0.02% 429

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's NAGE Position: Q2 2026 in Review

Essential Partners reduced its Niagen Bioscience (NAGE) stake by 84% in Q2 2026, selling an estimated $4.7K and leaving 227 shares worth $724. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

Essential Partners first reported a position in NAGE in Q2 2025 and has held it in 5 quarters since. The position peaked at $61.3K in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Essential Partners held 227 shares of Niagen Bioscience worth $724 as of Q2 2026.
  • Essential Partners sold 1,157 Niagen Bioscience shares in Q2 2026, an estimated $4.7K.
  • Niagen Bioscience made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2373 holding.
  • Essential Partners first reported a position in Niagen Bioscience in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Niagen Bioscience position peaked at $61.3K in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.